Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
<p>Abstract</p> <p>Background</p> <p>Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful tre...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-03-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/11/90 |
| _version_ | 1811281232297721856 |
|---|---|
| author | Sun Jin Zhang Zhiyuan Wang Tongshan Chen Xiaofen Guo Renhua Shu Yongqian |
| author_facet | Sun Jin Zhang Zhiyuan Wang Tongshan Chen Xiaofen Guo Renhua Shu Yongqian |
| author_sort | Sun Jin |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC who developed resistance to TKI.</p> <p>Case presentation</p> <p>Two patients with advanced or metastatic NSCLC were treated with palliative chemotherapy followed by erlotinib/gefitinib. When TKI therapy failed, two cycles of chemotherapy were provided, which were followed by re-challenge with erlotinib or gefitinib.</p> <p>Conclusion</p> <p>NSCLC patients with acquired TKI resistance should be managed aggressively whenever possible. Subsequent chemotherapy and target treatment is one of the reasonable choices for those with an initial dramatic clinical response with erlotinib/gefitinib treatment. Further studies are warranted to substantiate the association of erlotinib /gefitinib treatment with the efficacy of NSCLC patients with acquired TKI failure.</p> |
| first_indexed | 2024-04-13T01:30:04Z |
| format | Article |
| id | doaj.art-93327200f08049e99b833ebd172539de |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-13T01:30:04Z |
| publishDate | 2011-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-93327200f08049e99b833ebd172539de2022-12-22T03:08:33ZengBMCBMC Cancer1471-24072011-03-011119010.1186/1471-2407-11-90Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancerSun JinZhang ZhiyuanWang TongshanChen XiaofenGuo RenhuaShu Yongqian<p>Abstract</p> <p>Background</p> <p>Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC who developed resistance to TKI.</p> <p>Case presentation</p> <p>Two patients with advanced or metastatic NSCLC were treated with palliative chemotherapy followed by erlotinib/gefitinib. When TKI therapy failed, two cycles of chemotherapy were provided, which were followed by re-challenge with erlotinib or gefitinib.</p> <p>Conclusion</p> <p>NSCLC patients with acquired TKI resistance should be managed aggressively whenever possible. Subsequent chemotherapy and target treatment is one of the reasonable choices for those with an initial dramatic clinical response with erlotinib/gefitinib treatment. Further studies are warranted to substantiate the association of erlotinib /gefitinib treatment with the efficacy of NSCLC patients with acquired TKI failure.</p>http://www.biomedcentral.com/1471-2407/11/90 |
| spellingShingle | Sun Jin Zhang Zhiyuan Wang Tongshan Chen Xiaofen Guo Renhua Shu Yongqian Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer BMC Cancer |
| title | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
| title_full | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
| title_fullStr | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
| title_full_unstemmed | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
| title_short | Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer |
| title_sort | subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non small cell lung cancer |
| url | http://www.biomedcentral.com/1471-2407/11/90 |
| work_keys_str_mv | AT sunjin subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT zhangzhiyuan subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT wangtongshan subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT chenxiaofen subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT guorenhua subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer AT shuyongqian subsequentchemotherapyreversesacquiredtyrosinekinaseinhibitorresistanceandrestoresresponsetotyrosinekinaseinhibitorinadvancednonsmallcelllungcancer |